Roscovitine has been reported to have anti-tumor effects in some cancer cell lines. The
phosphatidylinositol-3-kinase (PI3K) signaling, which activates protein kinase B (PKB)/Akt, is …

Purine analogue roscovitine, a cyclin-dependent kinase (CDK) inhibitor, has shown strong
anti-proliferative and pro-apoptotic effects in solid and hematologic cancers such as non …

Roscovitine, a purine analogue, has been considered for the treatment of cancer. Anti-
cancer therapeutic efficacy is being evaluated in clinical trials. However, the mechanisms …

Roscovitine has been reported to have anti-proliferative properties and is in process of
undergoing clinical trials. In addition to its intrinsic anticancer properties, it has recently been …

Roscovitine is a cyclin-dependent kinase inhibitor, which has been previously investigated
for its anticancer effects. It has also been confirmed that roscovitine can downregulate the …

Purpose. Hepatocellular carcinoma (HCC) is a common malignancy worldwide and has an
annual occurrence of one million new cases. Novel therapeutic strategies of increased …

Roscovitine, a cyclin-dependent kinases (CDKs) inhibitor, has been reported to have anti-
tumor effects in some cancer cell lines by inducing apoptosis. However, the exact underlying …

Abstract Seliciclib (CYC202, R-Roscovitine) is a 2, 6, 9-substituted purine analog that is
currently in phase II clinical trials as an anticancer agent. We show in this study that R …

The antitumor activity of roscovitine was tested in four cervical carcinoma cells: C33A, HCE‐
1, HeLa, and SiHa. The effects of roscovitine on ATP Lite assay, cell cycle, and apoptosis …

Cyclin-dependent kinases (Cdks) play essential roles in the intracellular controls of the cell
cycles. Roscovitine,[2-(R)-(1-ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine] …